The Power of Precision CD8+ tLNPs
The promise of in vivo cell therapy is immense: rewriting, engineering, or repairing cells directly inside the human body without the complex, costly infrastructure of traditional ex vivo manufacturing. But to transition this promise from theory to clinical reality, the industry must overcome its single greatest bottleneck: delivery.
Historically, standard lipid nanoparticles (LNPs) have been bound by default biological constraints—overwhelmingly trafficking to the liver. Unlocking the true potential of systemic in vivo therapeutics requires an escape from liver tropism. It demands absolute, cell-type-specific selectivity.
At Tiva Biosciences, we designed our targeted lipid nanoparticle (tLNP) technologies to solve this exact problem. Our goal is to make precision extrahepatic delivery accessible, scalable, and translationally robust. Platform maturity is earned through rigorous iteration; to date, we have completed 1,000+ LNP formulation runs, supporting our biopharma partners to achieve critical pipeline milestones.
Recently, we partnered with ACROBiosystems for an exhaustive, independent validation study on our CD8-eGFP-tLNP.
High Transfection Efficiency
In resting primary CD8+ T cells across human peripheral blood mononuclear cell (hPBMC) samples, our platform achieved ~88% target gene expression. Delivering genetic material to resting primary immune cells is notoriously difficult, making this high-efficiency threshold a massive victory for scalable in vivo engineering.
Cell-Type Specificity
The validation study confirmed <1% non-specific uptake in CD4+ helper T cells. This level of lineage-specific precision ensures that therapeutic adjustments are isolated entirely to the intended cytotoxic T-cell populations, drastically lowering off-target safety risks.
True Plug-and-Play Modularity
The study demonstrated that our Ready-to-Target binder kit successfully converted standard LNPs into highly selective CD8-tLNPs using a simple, straightforward mixing protocol.
Redefining What’s Possible for In Vivo Pipelines
We want to extend a massive thank you to the team at ACROBiosystems for their rigorous evaluation and collaborative spirit throughout this validation process.
For biopharma innovators pushing the boundaries of oncology, autoimmunity, and hematology, precision tropism is no longer a luxury—it is the foundational requirement for the next generation of medicine. Let’s connect to discuss how Tiva Biosciences can engineer custom ligand-functionalized tLNPs to unlock the full potential of your therapeutic pipeline.
👉 [Contact our team today to request a technical consultation or explore our Ready-to-Target Binder Kits.]
